Nonmalignant Hematology (PDF)

and acquired thrombotic and coagulation disorders. As
Medical Director of the Brigham and Women's Hospital and Dana Farber Cancer
Institute Anticoagulation Management Service, Dr Connors oversees
anticoagulation practices in outpatient clinical settings. She is also the
Medical Director of the Hemostatic Antithrombotic Stewardship program, a
multi-disciplinary care delivery program, to ensure judicious and optimal use
of anticoagulants and clotting factors across all BWH inpatient services. She
has participated in a variety of types of clinical trials focusing
on anticoagulation including investigator initiated, served on scientific
advisory boards for a number of companies, teaches extensively at many levels
including peers in CME courses as well as fellows and residents, and has
written numerous reviews and chapters in the area of thrombosis-hemostasis.

Margaret
Ragni is a
Professor of Medicine and Clinical Translational Science at the University
of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. She received her MD
from the University of Pittsburgh School of Medicine and a Master of Public
Health from the University of Pittsburgh School of Public Health. She completed
her residency and fellowship in hematology/oncology at the University of
Pittsburgh Medical Center in Pittsburgh, where she joined the faculty in 1983.
Dr. Ragni's research interests are in congenital and acquired disorders of
hemostasis and thrombosis, and, in, particular in novel therapeutics for
patients with hemophilia with and without inhibitors. She serves on the Medical
and Scientific Advisory Committee of the National Hemophilia Foundation (NHF),
the FDA Blood Products Advisory Committee, the Scientific Committee on
Hemostasis of the American Society of Hematology,and on the Medical Advisory
Board for the Foundation for Women and Girls with Blood Disorders (FWGBD). She
also served as Co-Chair for the 2014 ASH Annual Meeting; as Co-Chair of the
Research Committee of the Hemostasis & Thrombosis Research Society, and is
a member of the Research Committee of the American Thrombosis & Hemostasis
Network. She is past member of the Hemostasis Thrombosis Study Section of the
NHLBI, and Co-Chair of the Bleeding Disorders Subcommittee of the NHLBI State
of the Science Symposium. She serves on Scientific Advisory Boards for Alnylam,
Baxalta, Biogen, and Biomarin. She has conducted numerous clinical
trials, observational studies, retrospective data base analyses,
cost-effectiveness analyses, and investigator-initiated new drug trials in
hemophilia and von Willebrand disease. She is the medical director of the
Hemophilia Center of Western PA, providing care for patients with bleeding and
clotting disorders, teach and mentor medical students, residents, fellows, and
young faculty.